Why the study?
Does adjunctive triglyceride-lowering therapy reduce residual atherosclerotic cardiovascular disease risk in high-risk patients optimally treated with statins?
Does adjunctive triglyceride-lowering therapy reduce residual atherosclerotic cardiovascular disease risk in high-risk patients optimally treated with statins?
There remains an unmet need for adjunctive therapies targeting hypertriglyceridemia to reduce residual cardiovascular risk in statin-treated patients, with ongoing trials of omega-3 fatty acids expected to provide further evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ganda et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: